Literature DB >> 15147983

Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract.

Cédric Gaudineau1, Rachel Beckerman, Sarah Welbourn, Karine Auclair.   

Abstract

The Ginkgo biloba extract EGb761 was tested for its ability to inhibit the major human cytochrome P450 enzymes (CYPs). The full extract was found to strongly inhibit CYP2C9 (Ki = 14+/- 4 microg/mL), and to a lesser extent, CYP1A2 (Ki = 106 +/- 24 microg/mL), CYP2E1 (Ki = 127 +/- 42 microg/mL), and CYP3A4 (Ki = 155 +/- 43 microg/mL). The terpenoidic and flavonoidic fractions of the extract were tested separately against the same P450s to identify the source of inhibition by EGb761. The terpenoidic fraction inhibited only CYP2C9 (Ki = 15 +/-6 microg/mL) whereas the flavonoidic fraction of EGb761 showed high inhibition of CYP2C9, CYP1A2, CYP2E1, and CYP3A4 (Ki's between 4.9 and 55 microg/mL). The flavonoidic fraction was further fractionated using extraction and chromatography. Inhibition studies indicated that the majority of these fractions inhibited P450s at a significant level (IC50 < 40 microg/mL).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147983     DOI: 10.1016/j.bbrc.2004.04.139

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

Review 1.  Drug interactions with herbal medicines.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

Review 2.  Interaction between warfarin and Chinese herbal medicines.

Authors:  Yan Ting Chua; Xiang Ling Ang; Xi Ming Zhong; Kei Siong Khoo
Journal:  Singapore Med J       Date:  2015-01       Impact factor: 1.858

Review 3.  Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine.

Authors:  Leda Marina Pomes; Giovanna Gentile; Maurizio Simmaco; Marina Borro; Paolo Martelletti
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

4.  Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects.

Authors:  Feng Shao; Hongwen Zhang; Lijun Xie; Juan Chen; Sufeng Zhou; Jinsong Zhang; Jinru Lv; Weiwen Hao; Yunsu Ma; Yun Liu; Ning Ou; Wei Xiao
Journal:  Eur J Clin Pharmacol       Date:  2017-01-20       Impact factor: 2.953

5.  Identification of Ginkgo biloba as a novel activator of pregnane X receptor.

Authors:  Eugene Y H Yeung; Tatsuya Sueyoshi; Masahiko Negishi; Thomas K H Chang
Journal:  Drug Metab Dispos       Date:  2008-08-25       Impact factor: 3.922

6.  Study of the upregulation of the activity of cytochrome P450 3A isoforms by Astragalus injection and Astragalus granules in rats and in cells.

Authors:  Yongli Zhang; Ling Huang; Huichang Bi; Yuqiang Cui; Jingqing Li; Xiangsheng Wang; Xiaoling Qin; Jiangying Chen; Min Huang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-07-14       Impact factor: 2.441

7.  Bioactivities of major constituents isolated from Angelica sinensis (Danggui).

Authors:  Wen-Wan Chao; Bi-Fong Lin
Journal:  Chin Med       Date:  2011-08-19       Impact factor: 5.455

8.  Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.

Authors:  G Zadoyan; D Rokitta; S Klement; A Dienel; R Hoerr; T Gramatté; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2011-12-21       Impact factor: 2.953

Review 9.  Updates on the clinical evidenced herb-warfarin interactions.

Authors:  Beikang Ge; Zhen Zhang; Zhong Zuo
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-18       Impact factor: 2.629

Review 10.  Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein.

Authors:  Hyun-Jong Cho; In-Soo Yoon
Journal:  Evid Based Complement Alternat Med       Date:  2015-01-06       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.